Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).
Authors: Allison Marie Bock, Sandeep Raj, Sharmila Giri, Lori Ann Leslie, Dilan Anil Patel, Madiha Iqbal, Natalie Sophia Grover, Boyu Hu, Miguel-Angel Perales, Grzegorz S. Nowakowski
Journal: Journal of Clinical Oncology (2024)

TPS7100 Background: Despite the promising efficacy of CAR-T for patients with relapsed or refractory (R/R) large B-cell lymphomas (LBCL), more than 60% of patients will relapse, the majority of which occur in the first 6 months. Approximately 30% of patients with LBCL treated with CAR-T achieve a partial response (PR) on day 30 (D30) PET-CT assessment. Of patients in a D30 PR, 70% will eventually progress, yet the standard of care remains close observation. Early consolidative treatment strategies utilizing therapies with a different mechanism of action may improve outcomes, but there are currently no reliable biomarkers. Epcoritamab (Epco), a bispecific antibody directed against CD20 and CD3, has been approved by the FDA for LBCL patients who relapse after at least 2 lines of therapy. In the phase 2 study, Epco was associated with an overall response rate (ORR) of 63% and a complete response (CR) rate of 39%, including similar responses in a subset of patients who were relapsed 100 days post CAR-T. This study is a trial-in-progress that will evaluate the efficacy of epco compared to observation for patients with LBCLs achieving a PR on D30 post CAR-T PET-CT assessment. Methods: This is an investigator-initiated, randomized, phase II, multicenter, open-label study (NCT06238648) evaluating epco monotherapy for a fixed duration of 12 cycles compared to observation for LBCL patients with D30 PR after standard of care CAR-T. A maximum of 120 patients will be randomized 1:1 to epco or observation across 10 academic centers. Stratification factors include line of CAR-T (second vs third line) and costimulatory domain (CD28 vs 4-1BB). Key inclusion criteria include PET evidence of a D30 PR. non-bulky disease ( &lt;7.5cm), ANC of &gt;1000, hemoglobin &gt;7 g/dL if asymptomatic or &gt;8 if symptomatic, platelet count &gt;50,000. G-CSF, pRBCs and platelet transfusions are allowed. Key exclusion criteria include prior anti CD20xCD3 bispecific antibody therapy, ongoing or uncontrolled CRS or ICANS, and active or symptomatic CNS disease. Epco is administered subcutaneously at a dose of 0.16mg on day 1, 0.8mg on day 8, prior to full dose of 48mg on day 15. Epco is administered weekly in 28 day cycles (C) for C1-3, on day 1 and 15 of C4-9 and on day 1 of C10-12. PET-CT response is assessed by the 2014 Lugano criteria after 2 cycles, and then every 3 months during active treatment. The primary objective is efficacy, measured as conversion from D30 PR to CR. The secondary endpoints include frequency and severity of treatment emergent adverse events, ORR, duration of response, duration of complete response, progression free survival, event free survival, and overall survival. Peripheral blood samples will be collected pre-treatment and during treatment to assess for biomarkers of response and resistance. The study was activated in January 2024 and recruitment is ongoing. Clinical trial information: NCT06238648 .